WO2006015283A3 - Treatment of benign prostatic hyperplasia - Google Patents

Treatment of benign prostatic hyperplasia Download PDF

Info

Publication number
WO2006015283A3
WO2006015283A3 PCT/US2005/027133 US2005027133W WO2006015283A3 WO 2006015283 A3 WO2006015283 A3 WO 2006015283A3 US 2005027133 W US2005027133 W US 2005027133W WO 2006015283 A3 WO2006015283 A3 WO 2006015283A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
benign prostatic
prostatic hyperplasia
lonidamine
prophylaxis
Prior art date
Application number
PCT/US2005/027133
Other languages
French (fr)
Other versions
WO2006015283A2 (en
Inventor
George Tidmarsh
Original Assignee
Threshold Pharmaceuticals Inc
George Tidmarsh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Threshold Pharmaceuticals Inc, George Tidmarsh filed Critical Threshold Pharmaceuticals Inc
Priority to JP2007523870A priority Critical patent/JP2008508316A/en
Publication of WO2006015283A2 publication Critical patent/WO2006015283A2/en
Publication of WO2006015283A3 publication Critical patent/WO2006015283A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A method for treatment or prophylaxis of benign prostatic hyperplasia by administration of lonidamine or a lonidamine analog is provided. Also provided are unit dosage forms of lonidamine and lonidamine analogs useful for such treatment and prophylaxis.
PCT/US2005/027133 2004-07-29 2005-07-29 Treatment of benign prostatic hyperplasia WO2006015283A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007523870A JP2008508316A (en) 2004-07-29 2005-07-29 Treatment of benign prostatic hyperplasia

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US59283304P 2004-07-29 2004-07-29
US60/592,833 2004-07-29
US66106705P 2005-03-11 2005-03-11
US60/661,067 2005-03-11

Publications (2)

Publication Number Publication Date
WO2006015283A2 WO2006015283A2 (en) 2006-02-09
WO2006015283A3 true WO2006015283A3 (en) 2006-06-22

Family

ID=35787884

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/027133 WO2006015283A2 (en) 2004-07-29 2005-07-29 Treatment of benign prostatic hyperplasia

Country Status (2)

Country Link
JP (1) JP2008508316A (en)
WO (1) WO2006015283A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7898642B2 (en) 2004-04-14 2011-03-01 Asml Netherlands B.V. Lithographic apparatus and device manufacturing method
CA3010615C (en) 2016-01-14 2024-02-20 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
EP3564214A1 (en) 2018-05-04 2019-11-06 Universita' Degli Studi G. D Annunzio Chieti - Pescara Indazole derivatives as modulators of the cannabinoid system

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5458597A (en) * 1993-11-08 1995-10-17 Zomed International Device for treating cancer and non-malignant tumors and methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5458597A (en) * 1993-11-08 1995-10-17 Zomed International Device for treating cancer and non-malignant tumors and methods

Also Published As

Publication number Publication date
JP2008508316A (en) 2008-03-21
WO2006015283A2 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
WO2004064735A3 (en) Treatment of benign prostatic hyperplasia
EA200401043A1 (en) Treatment of benign prostatic hyperplasia by the selective modulator of the androgen receptor (sarm)
MX2020008616A (en) Sublingual fentanyl spray.
MXPA05001298A (en) Compounds with the bicyclo[4.2.1]nonane system for the treatment of flaviviridae.
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
ECSP034922A (en) PIRROLOPIRIMIDINES
MXPA04005790A (en) Compounds and uses thereof for decreasing activity of hormone-sensitive lipase.
IN2005KO00312A (en)
PT1509232E (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer`s disease
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
WO2007025005A3 (en) Sustained release formulations of nalbuphine
NO20082088L (en) Acetidines as MEK inhibitors for the treatment of proliferative diseases
NO20100093L (en) Peptidomimetic protease inhibitors
NO20061625L (en) Treatment and / or prevention of urinary incontinence using prodrugs of gaba analogues
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
NO20056218L (en) Substituted pyrrole derivatives and their use as HMF-CoA reductase inhibitors
GB0222514D0 (en) Organic compounds
WO2006104870A3 (en) Methods of treating benign prostatic hyperplasia or lower urinary track symptoms by using pde 5 inhibitors
AU2002248319A1 (en) Pharmaceutical composition for the prevention and treatment of scar tissue
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
HUP0501111A2 (en) Treatment of severe pneumonia by administration of tissue factor pathway inhibitor
AU2003295336A1 (en) Use of etodoclac to treat hyperplasia
MXPA04011835A (en) Treatment for depression and anxiety by the combination of a pde iv inhibitor and an antidepressant or an anxiolytic agent.
WO2006015283A3 (en) Treatment of benign prostatic hyperplasia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007523870

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase